Education
About Us
Working with TipRanks
Follow Us
CalciMedica (CALC)
NASDAQ:CALC
CALC Stock Chart & Stats
$0.58
<$0.01(0.05%)
At close: 4:00 PM EST
$0.58
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$9.82M
Enterprise Value-$2.53M
Total Cash (Recent Filing)$13.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding14,409,431
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lead Program FocusAnalyst's recommendation highlights that concentrating resources on the Acute Pancreatitis program after strategic refocus away from the Acute Kidney Injury program aligns development with the company's primary value driver.
Pipeline DiversificationAdvancing a preclinical candidate toward an investigational new drug filing for pulmonary arterial hypertension provides meaningful pipeline diversification beyond the lead program.
Regulatory StrategySecuring regulatory agreement on a pivotal Acute Pancreatitis trial design could establish a first‑mover advantage in a market currently lacking approved treatments, enhancing commercial prospects.
Bears Say
Analyst SentimentAnalyst downgrade to neutral following the trial halt reflects increased uncertainty and may depress investor confidence until safety issues are addressed.
Clinical Trial HaltAn independent safety committee's recommendation to stop the KOURAGE trial due to a safety concern removes a key anticipated catalyst and heightens near‑term clinical and valuation uncertainty.
Safety Spillover RiskUncertainty over whether the safety finding in the kidney injury study will affect the design or prospects of the acute pancreatitis and pediatric programs raises the risk of material setbacks across the pipeline.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $9.82M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is May 18, 2026 which is in 74 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Mar 03, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.268.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Overvalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.28.
How many shares outstanding does CalciMedica have?
CalciMedica has 14,409,431 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 14.398%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
34.92% Insiders
2.88% Mutual Funds
10.19% Other Institutional Investors
49.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---